Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Not So Special? FDA Proposal Would Damage Streamlined 510(k) Submissions Program, Firms Say

This article was originally published in The Gray Sheet

Executive Summary

Agency’s proposed “special 510(k)” reforms, outlined in a recent draft guidance, will make the streamlined submissions program a lot less streamlined, and also less accessible to many device modifications, companies say.

You may also be interested in...



Proposed 510(k) Changes Elicit Some Industry Skepticism

Two 510(k) pilots from US FDA indicate the agency's desire for faster, easier clearances. But some observers aren’t sure if they’ll lead to real improvements.

FDA Looks To Expand Special 510(k) Program

US FDA released a draft guidance on the special 510(k) program in an effort to expand and improve the pathway.

Paradigm Persists: FDA Finalizes 510(k) Guidance Without Special 510(k) Changes

FDA has finalized an important guidance on 510(k) substantial equivalence, but decided to hold off on including sections that would overwrite the popular 1998 “The New 510(k) Paradigm” guidance that describe the abridged special and abbreviated 510(k) routes. Industry strongly objected to FDA’s proposed changes to the special 510(k) program in the 2011 draft 510(k) guidance.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031238

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel